31 Biotechnology & Immunology Cryopreserved Primary Human Cells
AMSBIO is a leading supplier of cryopreserved primary human cells for research from multiple organs including the lung, liver, intestine, and kidney. Drawing upon well-established partnerships with respected organ procurement organisations, AMSBIO has access to samples that allow direct isolation of a wide range of cells that retain their original morphological and functional characteristics.
Every batch of cells is validated for cell viability, morphology, plating efficiency and cell marker data. Cells are cultured for 5-7 days before being released and delivered with donor demographics and serology data demonstrating viral and mycoplasma negative status. The range of cryopreserved primary human cells from AMSBIO includes lung products (bronchial, tracheal and small airway epithelial cells, fibroblasts) ; kidney products (cortical cells, podocytes, proximal tubules, mesangial cells and glomerular endothelial cells) ; intestinal products (epithelial cells and myofibroblasts from ascending, transverse, descending colon, duodenum, jejunum and ilium) and liver products (Kupffer, stellate, sinusoidal endothelial and biliary epithelial cells and hepatocytes).
More information online:
ilmt.co/PL/Voyd 59663pr@reply-direct.com
Utilising CDX Mouse Models for Preclinical Studies in AML Research
TransCure bioServices has created cell line-derived xenograft (CDX) mouse models which will change the approach of researchers towards preclinical studies of cancer therapies for acute myeloid leukaemia (AML). With these models, researchers can obtain in-depth understanding of the effi cacy and toxicity of AML treatments, ultimately resulting in the development of superior therapies and bringing optimism to the numerous patients diagnosed with AML annually.
The latest mouse model for AML involves injecting AML luciferase tumour cell lines into mice, which permits the tracking of disease progression via bioluminescence imaging. By employing this model, researchers can now more effectively observe the in vivo behaviour of their AML therapies, while also acquiring a comprehensive understanding of the functional characterisation of AML pathogenesis.
More information online:
ilmt.co/PL/Voqp 60087pr@reply-direct.com
ADVERTORIAL INTEGRA’s Supporting Start-Ups Competition Won by Nanopath
Women-focused diagnostics start-up wins INTEGRA Biosciences’ EVOLVE pipettes Nanopath, a molecular diagnostics start-up, has been chosen as the fi rst winner of the recently launched INTEGRA supports start- ups competition, receiving 30 EVOLVE manual pipettes to help the company further develop its novel technology and translate the method to the clinic. Nanopath’s vision is to disrupt traditional testing methodologies for women in outpatient settings, employing a novel diagnostics platform that avoids the amplifi cation steps used in PCR, enabling rapid testing closer to the point of care.
Dr Amogha Tadimety, Co-Founder and CEO at Nanopath, commented: “Nanopath is a small company, and our team brings multifaceted expertise that spans assay development and engineering. With all our lab technicians using the same pipettes for each workfl ow, we can ensure consistency between users and build a solid foundation of data that we can trust. Winning the pipettes will undoubtedly positively impact Nanopath’s journey in a signifi cant way.”
INTEGRA awards 30 EVOLVE manual pipettes to Nanopath, a women-focused diagnostics start-up.
The Nanopath team was already using the ASSIST PLUS pipetting robot and the VOYAGER adjustable tip spacing pipette to automate the liquid handling workfl ows that underpin its technology, and this positive experience encouraged the team to apply for the INTEGRA prize: “Starting with these products made a tangible difference to a small company like ours. We were able to substantially increase our throughput at an early stage, quadrupling the number of patient samples we could run in a day, while providing superior accuracy. Building a relationship with a supportive supplier like INTEGRA is invaluable to start-ups like us, and we would highly recommend other innovative disruptors in the biotechnology sector to apply to this program.”
More information online:
ilmt.co/PL/v112 and
ilmt.co/PL/BKKQ
59982pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
